<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489697</url>
  </required_header>
  <id_info>
    <org_study_id>INCA06-FT/STIC-AVASTIN</org_study_id>
    <nct_id>NCT00489697</nct_id>
  </id_info>
  <brief_title>Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases</brief_title>
  <official_title>Medical and Economical Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bevacizumab, an anti-angiogenic agent, plus fluorouracil based chemotherapy is considered a
      new standard for the treatment of metastatic colorectal cancer. Contrast-enhanced ultrasound
      with gas-encapsulated microbubbles can be used to assess tumour vascularity, particularly
      hepatic metastases, and may become a useful tool for monitoring anti-angiogenic therapies.
      The aim of this prospective, multicenter, non-randomized study is to evaluate the usefulness
      of hepatic contrast-enhanced ultrasound to predict response to bevacizumab based chemotherapy
      in patient with metastatic colorectal cancer. The primary objective of this study is to
      compare the functional vascular changes related to bevacizumab based chemotherapy and
      evaluated by hepatic contrast-enhanced ultrasound with classic RECIST criteria. The secondary
      objectives are to do a characterization of the pharmacokinetic of bevacizumab, to explore the
      pharmacodynamic effects of bevacizumab on functional vascular changes of hepatic metastases
      evaluated by hepatic contrast-enhanced ultrasound and to analyze the possible relationships
      between treatment efficacy or toxicity and constitutional gene polymorphisms linked to the
      bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>functional vascular changes in tumour vascularity of hepatic metastases</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic of bevacizumab between each cure of bevacizumab based chemotherapy</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ratio cost/benefit of a strategy of therapeutic monitoring by contrast-enhanced ultrasound</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>evaluation of the response to bevacizumab based chemotherapy by RECIST criteria</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>bevacizumab-related toxicity</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response duration</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to disease progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival time</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1 (single arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient with histologically confirmed colorectal tumor treated in first line by a bevacizumab based chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>real-time contrast-enhanced ultrasound imaging (CEUS)</intervention_name>
    <description>Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)</description>
    <arm_group_label>1 (single arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed colorectal tumor

          -  first line treatment by a bevacizumab based chemotherapy

          -  Target hepatic metastases of size lower than 5 cm and higher than 5 mm detected by
             conventional ultrasonography and CT or MRI

          -  Life expectancy &gt; 2 months

          -  OMS status =&lt; 2

          -  Major surgery, open biopsy, or significant traumatic injury within 28 days prior to
             Day 0

          -  informed consent signed

        Exclusion Criteria:

          -  no target hepatic lesion detected by conventional ultrasonography

          -  Prior bevacizumab treatment

          -  Prior chemotherapy treatment for advanced disease

          -  Clinically significant cardiac disease (e.g. myocardial infarction or stroke within 12
             months, unstable angina, New York Heart Association (NYHA) Grade II or greater
             congestive heart failure not well controlled with medication, endocarditis and
             prosthetic valve) and any contraindications in sulphur hexafluoride administration

          -  Blood pressure &gt;= 180/110 mmHg

          -  Daily and chronic treatment by aspirin or AINS

          -  Anticipation of need for major surgical procedure within 7 days prior day 0

          -  Urine protein &gt; 1g/24 Hours

          -  Any contraindication in enhancing bevacizumab treatment

          -  Serious, uncontrolled, concurrent infection(s) or illness(es)

          -  pregnant and lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François TRANQUART, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de Tours, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry LECOMTE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de Tours, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno GIRAUDEAU, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>INSERM CIC 2002, Centre Hospitalier de Tours, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel RUSCH, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier de Tours, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU d'ANGERS</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC, Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Besancon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-André, CHRU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC, Centre René Gauducheau</name>
      <address>
        <city>Nantes St Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétrière, Assistance Publique Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Milétrie, CHRU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré, CHRU Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC, Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bleuzen A, Huang C, Olar M, Tchuenbou J, Tranquart F. Diagnostic accuracy of contrast-enhanced ultrasound in focal lesions of the liver using cadence contrast pulse sequencing. Ultraschall Med. 2006 Feb;27(1):40-8.</citation>
    <PMID>16470478</PMID>
  </reference>
  <reference>
    <citation>Forsberg F, Ro RJ, Potoczek M, Liu JB, Merritt CR, James KM, Dicker AP, Nazarian LN. Assessment of angiogenesis: implications for ultrasound imaging. Ultrasonics. 2004 Apr;42(1-9):325-30.</citation>
    <PMID>15047306</PMID>
  </reference>
  <reference>
    <citation>Broillet A, Hantson J, Ruegg C, Messager T, Schneider M. Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies. Acad Radiol. 2005 May;12 Suppl 1:S28-33.</citation>
    <PMID>16106543</PMID>
  </reference>
  <reference>
    <citation>Niermann KJ, Fleischer AC, Donnelly EF, Schueneman AJ, Geng L, Hallahan DE. Sonographic depiction of changes of tumor vascularity in response to various therapies. Ultrasound Q. 2005 Jun;21(2):61-7; quiz 149, 153-4.</citation>
    <PMID>15905816</PMID>
  </reference>
  <reference>
    <citation>Preda A, Novikov V, Möglich M, Turetschek K, Shames DM, Brasch RC, Cavagna FM, Roberts TP. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging. 2004 Nov;20(5):865-73.</citation>
    <PMID>15503324</PMID>
  </reference>
  <reference>
    <citation>Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005 Feb 1;65(3):671-80.</citation>
    <PMID>15705858</PMID>
  </reference>
  <reference>
    <citation>Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004 Jul-Aug;38(7-8):1258-64. Epub 2004 Jun 8. Review.</citation>
    <PMID>15187215</PMID>
  </reference>
  <reference>
    <citation>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.</citation>
    <PMID>15175435</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <last_update_submitted>January 2, 2017</last_update_submitted>
  <last_update_submitted_qc>January 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <name_title>Directrice de la Recherche et des Affaires Médicales</name_title>
    <organization>University Hospital Tours</organization>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>hepatic metastases</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>anti-angiogenic agent</keyword>
  <keyword>chemotherapy regimens</keyword>
  <keyword>tumor vascularity</keyword>
  <keyword>Contrast-enhanced ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

